Clinical Trial Update: Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC [Phase 2]

View source ↗

Summary

Clinical trial evaluating Gefitinib versus Docetaxel as second-line therapy for patients with wild-type EGFR non-small cell lung cancer (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN